Pharmaceutical Technology on MSN

BMS brings the buzz around late-stage readouts amid a so-so Q1

BMS is looking to Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy to drive ...

Is Bristol Myers Squibb the Best Bargain in Big Pharma?

Bristol Myers Squibb's valuation metrics show the stock is a bona fide bargain. However, valuation metrics can be misleading ...